Key result
Cardiac allograft vasculopathy is driven by both alloimmune and nonimmunologic factors, requiring optimal management of cardiovascular risk factors and novel immunosuppressive agents.
Population
Patients with transplanted hearts at risk for or developing cardiac allograft vasculopathy
Design
Review
Authors
Loading...
May warrant intensified CV risk factor control post-transplant; leaves open optimal novel immunosuppressant strategies pending prospective trials.
Cardiac allograft vasculopathy is a complex disease driven by both immunologic and non-immunologic factors, highlighting the need for comprehensive risk factor management and advanced immunosuppressive therapies in heart transplant recipients.
Giuseppe Vassalli (2003) conducted a review in Cardiac allograft vasculopathy. Cardiac allograft vasculopathy is driven by both alloimmune and nonimmunologic factors, requiring optimal management of cardiovascular risk factors and novel immunosuppressive agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: